While the coexistence of TP53 mutations has been associated with reduced efficacy of EGFR-TKIs in NSCLC, there is no evidence to suggest that alterations in TP53 impact the effectiveness of MET-TKIs (Canale et al., 2017; Fujino et al., 2021). This evidence concerns the gene TP53 and non-small cell lung carcinoma.